PNC Financial Services Group
MAZE

PNC Financial Services Group’s Maze Therapeutics MAZE Stock Holding History

PNC Financial Services Group’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$955 Sell
32
-26
-45% -$681 ﹤0.01% 4850
2026
Q1 		$1.73K Hold
58
– – ﹤0.01% 4626
2025
Q4 		$2.4K Sell
58
-35
-38% -$1.2K ﹤0.01% 4486
2025
Q3 		$2.41K Buy
+93
New +$1.57K ﹤0.01% 4446

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

PNC Financial Services Group's MAZE Position: Q2 2026 in Review

PNC Financial Services Group reduced its Maze Therapeutics (MAZE) stake by 45% in Q2 2026, selling an estimated $681 and leaving 32 shares worth $955. The position accounts for ﹤0.01% of the portfolio, ranked #4850.

PNC Financial Services Group first reported a position in MAZE in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.41K in Q3 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • PNC Financial Services Group held 32 shares of Maze Therapeutics worth $955 as of Q2 2026.
  • PNC Financial Services Group sold 26 Maze Therapeutics shares in Q2 2026, an estimated $681.
  • Maze Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4850 holding.
  • PNC Financial Services Group first reported a position in Maze Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • PNC Financial Services Group's Maze Therapeutics position peaked at $2.41K in Q3 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.